Plus Therapeutics (NASDAQ:PSTV) Price Target Raised to $20.50

Plus Therapeutics (NASDAQ:PSTV) had its target price upped by Ascendiant Capital Markets from $20.00 to $20.50 in a report released on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities analysts also recently commented on PSTV. HC Wainwright decreased their target price on Plus Therapeutics from $8.00 to $5.50 and set a “buy” rating for the company in a report on Friday, March 28th. D Boral Capital downgraded Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, May 5th. Finally, D. Boral Capital restated a “hold” rating on shares of Plus Therapeutics in a report on Monday, May 5th.

Plus Therapeutics Stock Performance

NASDAQ:PSTV opened at $0.33 on Thursday. The firm has a market cap of $5.53 million, a PE ratio of -0.13 and a beta of 0.64. Plus Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $2.40. The business has a 50 day moving average price of $0.59 and a 200-day moving average price of $0.96.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings data on Friday, May 30th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.39). The firm had revenue of $1.06 million during the quarter, compared to analysts’ expectations of $1.11 million. Research analysts predict that Plus Therapeutics will post -2.3 EPS for the current year.

Hedge Funds Weigh In On Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. Virtu Financial LLC acquired a new position in Plus Therapeutics, Inc. (NASDAQ:PSTV) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 40,030 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned approximately 0.24% of Plus Therapeutics at the end of the most recent quarter. 3.28% of the stock is owned by institutional investors and hedge funds.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.